Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Last trade$1.38
Day change-$0.26 (-15.85%)
Day range$1.36 – $1.64
Volume366,007
Market cap$298M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$297.82M
Price / earnings
—
Price / book
1.42×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.03×
Profitability
Earnings per share
-$0.54
Return on assets
-37.63%
Return on equity
-47.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.74×
Quick ratio
8.74×
Cash ratio
3.21×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$85.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IPSC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$109.16M
$4.17M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$109.16M
$4.17M
Selling, general and administrative
$7.15M
$5.79M
$6.58M
$956K
$6.84M
$7.81M
$8.41M
$7.76M
Research and development
$18.06M
$19.6M
$17.11M
$19.7M
$22.53M
$26.86M
$26.58M
$29.38M
Total operating expenses
$25.21M
$36.53M
$23.68M
$20.65M
$36.12M
$34.66M
$34.99M
$41.46M
Operating income
-$25.21M
-$36.53M
-$23.68M
-$20.65M
-$36.12M
-$34.66M
$74.18M
-$37.28M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$23.45M
-$34.55M
-$21.65M
-$19.24M
-$34.42M
-$32.54M
$76.56M
-$34.3M
Income taxes
$0
$0
$0
-$68K
$0
$0
$0
$1.78M
Net income
-$23.45M
-$34.55M
-$21.65M
-$19.17M
-$34.42M
-$32.54M
$76.56M
-$36.07M
Net income attributable to common shareholders
-$23.45M
-$34.55M
-$21.65M
-$19.17M
-$34.42M
-$32.54M
$76.56M
-$36.07M
EBITDA
-$23.02M
-$22.77M
-$20.68M
-$17.1M
-$26.23M
-$31.46M
$77.4M
-$29.64M
Basic earnings per share
-$0.11
-$0.17
-$0.11
-$0.22
-$0.40
-$0.38
$0.89
-$0.42
Diluted earnings per share
-$0.11
-$0.17
-$0.11
-$0.22
-$0.40
-$0.38
$0.89
-$0.42
Recent news
Company coverage with links to the original publishers.
The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.
The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.
GT Biopharma announced its third cancer drug, GTB-5550, entered Phase 1 clinical trials on May 14, 2026, marking the company's first expansion into solid tumors. Despite having three drugs in human trials—unusual for a micro-cap—the company trades at a significant valuation discount compared to peers, with only ~$9 million in cash and a runway into late 2026. The gap between its scientific promise and market valuation presents both opportunity and substantial risk, with near-term catalysts including clinical data updates and financing announcements expected in H2 2026.
Century Therapeutics reported Q1 2026 financial results with $217.0 million in cash runway extending into 1Q 2029. The company's lead program CNTY-813, an iPSC-derived islet therapy for type 1 diabetes, remains on track for IND submission in 4Q 2026 with initial clinical data expected in 2H 2027. CNTY-308, a CD19-targeted CAR-iT cell therapy, is progressing toward clinical initiation in 2026. R&D expenses decreased to $17.1 million from $26.6 million year-over-year due to personnel reductions and lower clinical trial spending.
The iPSC-derived NK cells clinical trial pipeline is experiencing significant momentum with 12+ companies developing 15+ pipeline therapies. Key players including Century Therapeutics, Fate Therapeutics, Cartherics, and others are advancing promising candidates like CNTY-101, FT522, and CTH-401 across various clinical stages. Recent developments include Century's CNTY-101 continuation in Phase I/II trials and Fate's positive initial data from FT522 in relapsed/refractory B-cell lymphoma, positioning iPSC-derived NK cells as a cornerstone of next-generation cancer immunotherapy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.